Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.

BACKGROUND & AIMS Dietary exposure to aflatoxin is an important risk factor for hepatocellular carcinoma (HCC). However, little is known about the genomic features and mutations of aflatoxin-associated HCCs compared with HCCs not associated with aflatoxin exposure. We investigated the genetic features of aflatoxin-associated HCC that can be used to differentiate them from HCCs not associated with this carcinogen. METHODS We obtained HCC tumor tissues and matched non-tumor liver tissues from 49 patients, collected from 1990 through 2016, at the Qidong Liver Cancer Hospital Institute in China-a high-risk region for aflatoxin exposure (38.2% of food samples test positive for aflatoxin contamination). Somatic variants were identified using GATK Best Practices Pipeline. We validated part of the mutations from whole-genome sequencing and whole-exome sequencing by Sanger sequencing. We also analyzed genomes of 1072 HCCs, obtained from 5 datasets from China, the United States, France, and Japan. Mutations in 49 aflatoxin-associated HCCs and 1072 HCCs from other regions were analyzed using the Wellcome Trust Sanger Institute mutational signatures framework with non-negative matrix factorization. The mutation landscape and mutational signatures from the aflatoxin-associated HCC and HCC samples from general population were compared. We identified genetic features of aflatoxin-associated HCC, and used these to identify aflatoxin-associated HCCs in datasets from other regions. Tumor samples were analyzed by immunohistochemistry to determine microvessel density and levels of CD34 and CD274 (PD-L1). RESULTS Aflatoxin-associated HCCs frequently contained C>A transversions, the sequence motif GCN, and strand bias. In addition to previously reported mutations in TP53, we found frequent mutations in the adhesion G protein-coupled receptor B1 gene (ADGRB1), which were associated with increased capillary density of tumor tissue. Aflatoxin-associated HCC tissues contained high-level potential mutation-associated neoantigens, and many infiltrating lymphocytes and tumors cells that expressed PD-L1, compared to HCCs not associated with aflatoxin. Of the HCCs from China, 9.8% contained the aflatoxin-associated genetic features, whereas 0.4%-3.5% of HCCs from other regions contained these genetic features. CONCLUSIONS We identified specific genetic and mutation features of HCCs associated with aflatoxin exposure, including mutations in ADGRB1, compared to HCCs from general populations. We associated these mutations with increased vascularization and expression of PD-L1 in HCC tissues. These findings might be used to identify patients with HCC due to aflatoxin exposure, and select therapies.

[1]  Olfat Al-Harazi,et al.  Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells , 2015, Molecular Cancer.

[2]  Niko Välimäki,et al.  CTCF/cohesin-binding sites are frequently mutated in cancer , 2015, Nature Genetics.

[3]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[4]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[5]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[6]  Peter J. Campbell,et al.  C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency , 2014, Genome research.

[7]  R. Teschke Traditional Chinese Medicine Induced Liver Injury , 2014, Journal of clinical and translational hepatology.

[8]  R. Purcell,et al.  The BAI subfamily of adhesion GPCRs: synaptic regulation and beyond. , 2014, Trends in pharmacological sciences.

[9]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[10]  P. A. Futreal,et al.  Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool , 2013, Science Translational Medicine.

[11]  K. Kinzler,et al.  Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing , 2013, Science Translational Medicine.

[12]  S. Thorgeirsson,et al.  Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. , 2013, Carcinogenesis.

[13]  Zhongming Zhao,et al.  VirusFinder: Software for Efficient and Accurate Detection of Viruses and Their Integration Sites in Host Genomes through Next Generation Sequencing Data , 2013, PloS one.

[14]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[15]  Niruthika Sritharan,et al.  Genomic landscape of non-small-cell lung cancer in smokers and never-smokers , 2013, Thorax.

[16]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[17]  M. Stratton,et al.  Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.

[18]  William Stafford Noble,et al.  Integrative annotation of chromatin elements from ENCODE data , 2012, Nucleic acids research.

[19]  Felicia Wu,et al.  Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. , 2012, European journal of cancer.

[20]  Bin Tean Teh,et al.  Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes , 2012, Nature Genetics.

[21]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[22]  C. V. Jongeneel,et al.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.

[23]  Erwin G. Van Meir,et al.  Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development , 2011, Journal of Molecular Medicine.

[24]  J. Groopman,et al.  Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[26]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[27]  Yihai Cao,et al.  Adipose angiogenesis: quantitative methods to study microvessel growth, regression and remodeling in vivo , 2010, Nature Protocols.

[28]  Elias Campo Guerri,et al.  International network of cancer genome projects , 2010, Nature.

[29]  Yan Liu,et al.  Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment , 2010, Environmental health perspectives.

[30]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[31]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[32]  P. Chow,et al.  Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. , 2009, The Lancet. Oncology.

[33]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[34]  Hyunsuk Shim,et al.  Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. , 2009, Cancer research.

[35]  J. Uhm Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[36]  Timothy D Phillips,et al.  Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. , 2004, The American journal of clinical nutrition.

[37]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Groopman,et al.  Translational strategies for cancer prevention in liver , 2003, Nature Reviews Cancer.

[39]  S. Thorgeirsson,et al.  Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China , 2002, Hepatology.

[40]  L. Bulacio,et al.  Aflatoxin B1 content in patients with hepatic diseases. , 2002, Medicina.

[41]  Erwin G. Van Meir,et al.  Thrombospondins and tumor angiogenesis. , 2001, Trends in molecular medicine.

[42]  Yusuke Nakamura,et al.  A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis , 1997, Oncogene.

[43]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[44]  R. A. Metcalf,et al.  Mutational hot spot in the p53 gene in human hepatocellular carcinomas , 1991, Nature.

[45]  R. Metcalf,et al.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas. , 1991, Nature.